AIMT Insider Trading Activity and SEC Form 4 Filings
AIMT insider trading summary
No open-market insider purchases or sales of Aimmune Therapeutics, Inc. (AIMT) have been reported on SEC Form 4 in the past 12 months.
Latest AIMT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 13, 2020 | des Produits Nestle S.A. Societe | 10% Owner | Buy | $368.5M (10,681,704 @ $34.50) |
| Oct 13, 2020 | des Produits Nestle S.A. Societe | 10% Owner | Buy | $1.50B (43,435,583 @ $34.50) |
| May 27, 2020 | Patrick G Enright | Director | Sell | $0 (7,840 @ $0.00) |
| Mar 18, 2020 | Patrick G Enright | Director | Buy | $179K (16,213 @ $11.06) |
| Mar 17, 2020 | Patrick G Enright | Director | Buy | $1.1M (100,000 @ $11.40) |
| Mar 17, 2020 | Patrick G Enright | Director | Buy | $101K (8,787 @ $11.50) |
| Mar 13, 2020 | Andrew Oxtoby | Chief Commercial Officer | Buy | $44K (3,000 @ $14.76) |
| Mar 12, 2020 | Eric Bjerkholt | Chief Financial Officer | Buy | $15K (1,000 @ $15.10) |
| Mar 10, 2020 | Jayson Donald Alexander Dallas | President and CEO | Buy | $50K (2,665 @ $18.74) |
| Mar 9, 2020 | Eric Bjerkholt | Chief Financial Officer | Buy | $19K (1,000 @ $18.97) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.